589 related articles for article (PubMed ID: 35331783)
1. mRNA vaccines for COVID-19 and diverse diseases.
Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
3. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
4. Advances in COVID-19 mRNA vaccine development.
Fang E; Liu X; Li M; Zhang Z; Song L; Zhu B; Wu X; Liu J; Zhao D; Li Y
Signal Transduct Target Ther; 2022 Mar; 7(1):94. PubMed ID: 35322018
[TBL] [Abstract][Full Text] [Related]
5. Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2.
Lee KM; Lin SJ; Wu CJ; Kuo RL
Biomed J; 2023 Feb; 46(1):70-80. PubMed ID: 36642222
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 mRNA vaccines: Platforms and current developments.
Szabó GT; Mahiny AJ; Vlatkovic I
Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
[TBL] [Abstract][Full Text] [Related]
7. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
8. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
[TBL] [Abstract][Full Text] [Related]
9. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
[TBL] [Abstract][Full Text] [Related]
10. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses.
Kutikuppala LVS; Kourampi I; Kanagala RSD; Bhattacharjee P; Boppana SH
Med Sci (Basel); 2024 May; 12(2):. PubMed ID: 38804384
[TBL] [Abstract][Full Text] [Related]
11. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab.
Jarzebska NT; Frei J; Mellett M; Kündig TM; Pascolo S; Reichmuth AM
Methods Mol Biol; 2024; 2786():237-254. PubMed ID: 38814398
[TBL] [Abstract][Full Text] [Related]
12. Current Status and Future Perspectives on MRNA Drug Manufacturing.
Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
[TBL] [Abstract][Full Text] [Related]
13. mRNA Vaccines in the COVID-19 Pandemic and Beyond.
Hogan MJ; Pardi N
Annu Rev Med; 2022 Jan; 73():17-39. PubMed ID: 34669432
[TBL] [Abstract][Full Text] [Related]
14. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.
Mirtaleb MS; Falak R; Heshmatnia J; Bakhshandeh B; Taheri RA; Soleimanjahi H; Zolfaghari Emameh R
Int Immunopharmacol; 2023 Apr; 117():109934. PubMed ID: 36867924
[TBL] [Abstract][Full Text] [Related]
15. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.
Trougakos IP; Terpos E; Alexopoulos H; Politou M; Paraskevis D; Scorilas A; Kastritis E; Andreakos E; Dimopoulos MA
Trends Mol Med; 2022 Jul; 28(7):542-554. PubMed ID: 35537987
[TBL] [Abstract][Full Text] [Related]
17. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
Granados-Riveron JT; Aquino-Jarquin G
Biomed Pharmacother; 2021 Oct; 142():111953. PubMed ID: 34343897
[TBL] [Abstract][Full Text] [Related]
18. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
Deng Z; Tian Y; Song J; An G; Yang P
Front Immunol; 2022; 13():887125. PubMed ID: 35720301
[TBL] [Abstract][Full Text] [Related]
19. The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection.
Xue VW; Wong SCC; Li B; Cho WCS
Expert Opin Drug Discov; 2023 Jul; 18(7):769-780. PubMed ID: 37237360
[TBL] [Abstract][Full Text] [Related]
20. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
Jin L; Han Z; Zhao P; Sun K
Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
